Vidaza® (azacytidine) is now approved to treat newly diagnosed juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer, in pediatric patients who are at least one month old.

• Manufactured by Celgene, Vidaza first received FDA approval in 2004. In addition to treating JMML, it is also indicated to treat certain subtypes of myelodysplastic syndrome (MDS) in Both MDS and JMML occur when normal blood cell production is disrupted.
• Vidaza for JMML is administered via intravenous infusion once daily for seven days in a 28-day cycle, with patients receiving a minimum of three cycles and a maximum of The recommended dosing for JMML is:
  • 5mg/kg of the patient’s body weight for patients one month to less than one year old or weighing less than 10kg (22 pounds).
• 75mg/m² of the patient’s body surface area for patients at least one year of age who weigh 10kg or more.